Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trialAndrés Poveda, Nicolas Pécuchet, Richard T. Penson et al.|The Lancet Oncology|2021Cited by 412
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient dataPaul A. Cohen, Arjun Jeyarajah, Aime Powell et al.|Gynecologic Oncology|2019Cited by 121